Popular Stories

AstraZeneca Tag

  • All
  • Beauty
  • Biotechnology
  • Cannabis
  • Communications
  • Education
  • Energy
  • Entertainment
  • Environment
  • ETFs
  • Finance
  • Fitness
  • Food and Beverage
  • Healthcare
  • Hospitality
  • Insider Trading
  • Investing Ideas
  • Macro
  • Market Insight
  • Miscellaneous
  • Power
  • Real Estate
  • Retail
  • Sectors
  • Security
  • Startups
  • Technologies
  • Trending
  • Uncategorized
3 stocks to Avoid At All Costs

Genius Brands International, Inc. (NASDAQ: GNUS), formerly known as Pacific Entertainment Corporation, develops animated “content with a purpose” for toddlers to tweens worldwide. The Company’s programs include Superhero Kindergarten, developed in association with Stan Lee; Llama Llama streaming on Netflix; Rainbow Rangers on Nick Jr;...

5 Small Cap Tech Stocks to Boost your Portfolio in 2021

While Industries across the globe are grappling with the pandemic and its impact on their operations, Technology Industry has been focused on minimizing the impact and marching ahead with its innovations and breakthroughs, be it healthcare, contactless payments or big data analysis. We take a look...

5 Companies Bringing Innovation to the Fabry Disease Treatment Market

Fabry Disease also known as angiokeratoma corporis diffusum or alpha-galactosidase A deficiency, is an inherited disorder characterized by the buildup of globotriaosylceramide, a type of fat in the body’s cells and results in numerous disorders such as acroparesthesias (burning, tingling, or prickling sensation in extremities),...

Inovio Pharmaceuticals is Carving a Niche in the Immunotherapy Market

Inovio Pharmaceuticals (NASDAQ: INO), a late-stage biotechnology Company developing DNA-based immunotherapies and vaccines to combat cancer and infectious diseases, announced the grant of up to $9 million by the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for Coronavirus 2019-nCoV, a deadly new...

Can Nektar Therapeutics Bounce Back from its Massive Tumble?

Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical Company engaged in developing candidates for oncology, auto-immune and chronic pain, has announced the withdrawal of its application for oxycodegol (formerly NKTR-181), as it received adverse advisory committee decision from both Anesthetic and Analgesic Drug Products Advisory Committee, and...

Emerging Paradigms in the Sickle Cell Disease Treatment Market

According to an estimate by the Centers for Disease Control and Prevention (CDC), SCD affects over 100,000 Americans and is a major public health concern as it resulted in 75,000 hospitalizations between 1989 through 1993, and cost over $475 million. The Medical expenditure of children with...

G1 Therapeutics stock soars on news of NDA for Triaciclib

G1 Therapeutics (NASDAQ: GTHX) shares soared by almost 25% on the basis of news that it had a productive phase 2 meeting with the FDA for the company’s lead candidate Trilaciclib, a first-in-class myelopreservation agent that protects the bone marrow from damage by chemotherapy. The...

WordPress Video Lightbox Plugin